Caricamento...
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
BACKGROUND: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median progression-free survival of 12–18 months. There...
Salvato in:
| Pubblicato in: | J Transl Med |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5024442/ https://ncbi.nlm.nih.gov/pubmed/27634150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1027-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|